Neutrophil gelatinase-associated lipocalin (NGAL): a promising biomarker of contrast-induced nephropathy after computed tomography

References

• Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. JAMA. 2006;295:2765–2779
   PubMed Web of Science ®Google Scholar
• Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39:930–936
   PubMed Web of Science ®Google Scholar
• Solomon R. Contrast media nephropathy – how to diagnose and how to prevent? Nephrol Dial Transplant. 2007;22:1812–1815
   PubMed Web of Science ®Google Scholar
• Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens. 2008;17:127–132
   PubMed Web of Science ®Google Scholar
• Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol. 2006;17:1503–1520
   PubMed Web of Science ®Google Scholar
• Devarajan P. Neutrophil gelatinase-associated lipocalin – an emerging troponin for kidney injury. Nephrol Dial Transplant. 2008;23:3737–3743
   PubMed Web of Science ®Google Scholar
• Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med. 2010;4:265–280
   PubMed Web of Science ®Google Scholar
• Cowland JB, Sorensen OE, Schested M, Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1β but not by TNF-α. J Immunol. 2003;171:6630–6639
   PubMed Web of Science ®Google Scholar
• Mishra J, Mori K, Ma Q, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2004;15:3073–3082
   PubMed Web of Science ®Google Scholar
• Schmidt-Ott KM, Mori K, Li JY, et al. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2007;18:407–413
   PubMed Web of Science ®Google Scholar
• Devarajan P. Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle. Cancer Ther. 2007;5(B):463–470
   PubMedGoogle Scholar
• Yuen PST, Jo S-K, Holly MK, Hu X, Star RA. Ischemic and nephrotoxic acute renal failure are distinguished by their broad transcriptomic responses. Physiol Genomics. 2006;25:375–386
   PubMed Web of Science ®Google Scholar
• Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel urinary biomarker for ischemic injury. J Am Soc Nephrol. 2003;4:2534–2543
   Web of Science ®Google Scholar
• Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest. 2005;115:610–621
   PubMed Web of Science ®Google Scholar
• Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol. 2006;26:287–292
   PubMed Web of Science ®Google Scholar
• Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, et al. Could neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C predict the development of contrast-induced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values? Kidney Blood Press Res. 2007;30:408–415
   PubMed Web of Science ®Google Scholar
• Ling W, Zhaohui N, Ben H, et al. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract. 2008;108:c176–c181
   PubMed Web of Science ®Google Scholar
• Hirsch R, Dent C, Pfriem H, et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol. 2007;22:2089–2095
   PubMed Web of Science ®Google Scholar
• Shaker OG, El-Shehaby A, El-Khatib M. Early diagnostic markers for contrast nephropathy in patients undergoing coronary angiography. Angiology. 2010;61:731–736
   PubMed Web of Science ®Google Scholar
• Haase M, Bellomo R, Devarajan P, Schlattman P, Haase-Fielitz A, the NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;54:1012–1024
   PubMed Web of Science ®Google Scholar
• Rao QA, Newhouse JH. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology. 2006;239:392–397
   PubMed Web of Science ®Google Scholar
• Rudnick MR, Goldfarb S, Tumlin J. Contrast-induced nephropathy: is the picture any clearer? Clin J Am Soc Nephrol. 2008;3:261–262
   PubMed Web of Science ®Google Scholar
• Solomon R. Contrast-induced acute kidney injury: is there a risk after intravenous contrast? Clin J Am Soc Nephrol. 2008;3:1242–1243
   PubMed Web of Science ®Google Scholar
• Dent CL, Ma Q, Dastrala S, et al. Plasma NGAL predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study. Crit Care. 2007;11:R127
   PubMed Web of Science ®Google Scholar
• Filiopoulos V, Biblaki D, Lazarou D, et al. Plasma neutrophil gelatinase-associated lipocalin (NGAL) as an early predictive marker of contrast-induced nephropathy in hospitalized patients undergoing computed tomography. Clin Kidney J. 2013;6:578–583
   PubMedGoogle Scholar
• McIlroy DR, Wagener G, Lee HT. Neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery: the effect of baseline renal function on diagnostic performance. Clin J Am Soc Nephrol. 2010;5:211–219
   PubMed Web of Science ®Google Scholar
• Solomon RJ, Mehran R, Natarajan MK, et al. Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol. 2009;4:1162–1169
   PubMed Web of Science ®Google Scholar
• Mitchell AM, Jones AE, Tumlin JA, Kline JA. Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting. Clin J Am Soc Nephrol. 2010;5:4–9
   PubMed Web of Science ®Google Scholar
• Weisbord SD, Mor MK, Resnick AL, Hartwig KC, Palevsky PM, Fine MJ. Incidence and outcomes of contrast-induced AKI following computed tomography. Clin J Am Soc Nephrol. 2008;3:1274–1281
   PubMed Web of Science ®Google Scholar
• Barrett B, Thomsen H, Katzberg R. Nephrotoxicity of low-osmolar iopamidol vs iso-osmolar iodixanol in renally impaired patients: the IMPACT study. Invest Radiol. 2006;41:815–821
   PubMed Web of Science ®Google Scholar
• Thomsen HS, Morcos SK, Erley CM, et al. Investigators in the abdominal computed tomography: the ACTIVE trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol. 2008;43:170–178
   PubMed Web of Science ®Google Scholar
• Kuhn M, Chen N, Sahani DV, et al. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. Am J Radiol. 2008;191:151–157
   Google Scholar
• Bolignano D, Coppolino G, Campo S, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transplant. 2008;23:414–416
   PubMed Web of Science ®Google Scholar
• Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int. 2011;80:806–821
   PubMed Web of Science ®Google Scholar
• Lacquantiti A, Buemi F, Lupica R, et al. Can neutrophil gelatinase-associated lipocalin help predict early contrast material-induced nephropathy? Radiology. 2013;267:86–93
   PubMed Web of Science ®Google Scholar
• Vanmassenhove J, Vanholder R, Nagler E, van Biesen W. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant. 2013;28:254–273
   PubMed Web of Science ®Google Scholar
• Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008;73:1008–1016
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sugaya T, Node K, Ueda Y, Koide H. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am J Kidney Dis. 2006;47:439–444
   PubMed Web of Science ®Google Scholar
• Bulent Gul CB, Gullulu M, Oral B, et al. Urinary IL-18: a marker of contrast-induced nephropathy following percutaneous coronary intervention? Clin Biochem. 2008;41:544–547
   PubMed Web of Science ®Google Scholar
• Kato K, Sato N, Yamamoto T, Iwasaki YK, Tanaka K, Mizuno K. Valuable markers for contrast-induced nephropathy in patients undergoing cardiac catheterization. Circ J. 2008;72:1499–1505
   PubMed Web of Science ®Google Scholar
• Bachorzewska-Gajewska H, Poniatowski B, Dobrzycki S. NGAL (neutrophil gelatinase-associated lipocalin) and L-FABP after percutaneous coronary interventions due to unstable angina in patients with normal serum creatinine. Adv Med Sci. 2009;54:221–224
   PubMed Web of Science ®Google Scholar
• Briguori C, Visconti G, Rivera NV, et al. Cystatin C and contrast-induced acute kidney injury. Circulation. 2010;121:2117–2122
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Yamauchi M, Musha H, Mikami T, Kawasaki K, Miyake F. Impact of contrast-induced nephropathy and cardiovascular events by serum cystatin C in renal insufficiency patients undergoing cardiac catheterization. Angiology. 2010;61:724–730
   PubMed Web of Science ®Google Scholar